<- Go Home
Savara Inc.
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
Market Cap
$1.3B
Volume
1.7M
Cash and Equivalents
$38.8M
EBITDA
-$133.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$85.6M
Profit Margin
N/A
52 Week High
$7.00
52 Week Low
$1.89
Dividend
N/A
Price / Book Value
7.59
Price / Earnings
-9.43
Price / Tangible Book Value
8.11
Enterprise Value
$1.2B
Enterprise Value / EBITDA
-8.73
Operating Income
-$133.2M
Return on Equity
79.95%
Return on Assets
-40.53
Cash and Short Term Investments
$204.1M
Debt
$30.1M
Equity
$176.0M
Revenue
N/A
Unlevered FCF
-$58.2M
Sector
Biotechnology
Category
N/A